---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-003750"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:08:04.549263+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Adial shareholders approve issuance of up to 3.0M shares upon warrant exercise

## Summary
- Proposal 1 approved: 432,915 for, 51,550 against, 6,621 abstain; enables exercise of warrants from Oct 2023 private placement.
- Proposal 2 (adjournment) also approved but not needed; votes: 436,338 for, 47,809 against, 6,939 abstain.
- Warrant exercise could dilute existing common stock by over 20%, subject to Nasdaq rules.

## SEC filing metadata
- accession: 0001213900-24-003750
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390024003750/0001213900-24-003750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390024003750/ea191680-8k_adialpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-003750
- JSON: https://secwatch.observer/filing/0001213900-24-003750.json
- Plain text: https://secwatch.observer/filing/0001213900-24-003750.txt

## Key facts
- Shareholder Votes
  ADIAL PHARMACEUTICALS, INC. shareholders approved Approval of adjournment of Special Meeting, if necessary, to permit further solicitation at the 2024-01-11 meeting.
  - Outcome: passed
  - Meeting: 2024-01-11
  source text: Proposal 2 : Approval of an adjournment of the Special Meeting to a later date, if necessary, to permit furth solicitation and vote of proxies in the event there are not sufficient votes in favor of the Warrant Exercise Proposal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390024003750/0001213900-24-003750-index.htm
- Shareholder Votes
  ADIAL PHARMACEUTICALS, INC. shareholders approved Approval of issuance of up to 3,007,092 shares of common stock upon exercise of warrants in connection with private placement at the 2024-01-11 meeting.
  - Outcome: passed
  - Meeting: 2024-01-11
  source text: Proposal 1 : Approval of, pursuant to Nasdaq listing rules, of the issuance of up to an aggregate of 3,007,092 shares of the Company's common stock upon the exercise of common stock purchase warrants issued or issuable to an institutional investor and designees of the placement agent in connection with the Company's private placement offering that closed on October 24, 2023 that may be equal to or exceed 20% of the Company's common stock outstanding before such offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390024003750/0001213900-24-003750-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.